Search Results - "Aranda, Nuria Pardo"

Genomic alterations profiling by liquid biopsy and their association to immune checkpoints inhibitors (ICI) response in a cohort of non-small cell lung cancer (NSCLC) patients by Callejo, Ana, Carbonell, Caterina, Iranzo, Patricia, Pardo Aranda, Nuria, Navarro, Alejandro, Martinez-Marti, Alex, Cedres Perez, Susana, Gutierrez, Raquel, Recasens, Sergi, Madrenas, Raquel, Sanchez, Laura, Saoudi, Nadia, Assaf, Juan David, Masnou, Mar, Frigola, Joan, Amat, Ramon, Felip, Enriqueta

“…Abstract only e21524 Background: In metastatic NSCLC, identification of biomarkers of response to immune checkpoint inhibitors (ICI) is still an unmet need…”
Get full text

Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1) by Iranzo, Patricia, Callejo, Ana, Pedrola, Anna, Pardo Aranda, Nuria, Navarro, Alejandro, Martinez-Marti, Alex, Cedres Perez, Susana, Ros, Javier, Assaf, Juan David, Saoudi, Nadia, Carbonell, Caterina, Amat, Ramon, Frigola, Joan, Jimenez, Jose, Dienstmann, Rodrigo, Palmer, Hector G., Vivancos, Ana, Felip, Enriqueta

“…Abstract only e15137 Background: APC and CTNNB1 mutations (mut) lead to an aberrant activation of the WNT pathway which has been linked to lack of benefit of…”
Get full text

Outcome of RAS mutated lung adenocarcinoma (ADC ) patients (pts) on standard chemotherapy (chemo) and immune checkpoint inhibitors (immuneCI) by Pardo Aranda, Nuria, Ruiz, Fiorella, Martinez Marti, Alex, Navarro, Alejandro, Cedres Perez, Susana, de la Fuente, Iris, Baste, Neus, Vivancos, Ana, Miquel, Josep M, Dienstmann, Rodrigo, Felip, Enriqueta

“…Abstract only…”
Get full text

Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI by Pardo Aranda, Nuria, Remon, Jordi, Martinez Marti, Alex, Martinez de Castro, Ana Maria, Cedres Perez, Susana, Navarro, Alejandro, Scheenaard, Eulalia, Piera, Adelaida, Carbonell, LLuisa, Vivancos, Ana, Felip, Enriqueta, Gámez Córdoba, Esther

“…Abstract only e20555 Background: EGFR mutant(EGFRm) NSCLC patients develop adquired resistance after 12 months on EGFR TKI. Acquired T790mutation(T790M) is the…”
Get full text

Outcome of KRAS mutated (m) non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (immuneCI) by Pardo Aranda, Nuria, Viaplana, Cristina, Remon, Jordi, Martinez Marti, Alex, Cedres Perez, Susana, Navarro, Alejandro, Martinez de Castro, Ana Maria, Villacampa, Guillermo, Carbonell, LLuisa, Hernando, Alberto, Vivancos, Ana, Dienstmann, Rodrigo, Felip, Enriqueta

“…Abstract only e20526 Background: The most frequent genetic alteration in advanced NSCLC is KRASm in ~25% of tumors. This event associates with smoking pattern…”
Get full text

Results of patients with thoracic cancers older than 70 years included in clinical trials: A center experience by Martinez Marti, Alex, Cabrera, Guadalupe, Ortiz, Carolina, Vilaro, Marta, Miquel, Josep M, Cedres Perez, Susana, Navarro, Alejandro, Pardo Aranda, Nuria, Martinez, Pablo, Piera, Adelaida, Carbonell, LLuisa, De la Fuente, Iris, Garcia, Silvia, Sansano, Irene, Felip, Enriqueta

“…Abstract only…”
Get full text

Analysis of clinical characteristics and outcomes of ALK positive (ALK+) patients treated with ALK inhibitors (ALKi) by Cedres Perez, Susana, Pardo Aranda, Nuria, Navarro, Alejandro, Martinez Marti, Alex, Martinez de Castro, Ana Maria, Cabrera, Guadalupe, Vilaro, Marta, Carbonell, LLuisa, de la Fuente, Iris, Piera, Adelaida, Martinez, Lidia, Hernandez-Losa, Javier, Sansano, Irene, Felip, Enriqueta

“…Abstract only…”
Get full text

Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types by Navarro, Alejandro, Arance, Ana, Reguart, Noemi, Paré, Laia, Galván, Patricia, Martinez Marti, Alex, Nuciforo, Paolo, Pardo Aranda, Nuria, Cedres Perez, Susana, Gaba, Lydia, Victoria, Iván, Vinolas, Nuria, Vivancos, Ana, Prat, Aleix, Felip, Enriqueta

“…Abstract only…”
Get full text

Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations by Martinez de Castro, Ana, Remon, Jordi, Cedres Perez, Susana, Navarro, Alejandro, Martinez Marti, Alexandre, Pardo Aranda, Nuria, Hernando, Alberto, Zeron-Medina, Jorge, Aguilar-Company, Juan, Scheenaard, Eulalia, Recasens, Sergi, Ruiz-Pace, Fiorella, Villacampa, Guillermo, Jimenez, Jose, Dienstmann, Rodrigo, Nuciforo, Paolo, Felip, Enriqueta, Vivancos, Ana

“…Abstract only e23103 Background: There is a growing need for accurate molecular diagnostics for proper targeted therapeutics selection in NSCLC patients (pts)…”
Get full text

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report by Cirauqui, Beatriz Cirauqui, García, Vanesa Quiroga, Rubio, Clara Lezcano, Miguel, Maria Iciar Pascual, Riera, Laia Capdevila, Aranda, Nuria Pardo, Martín, Sara Vizcaya, Martínez, Antonio Mariscal, Caruncho, Clara Rodríguez, Vila, Mireia Margelí

“…Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including…”
Get full text

Renal-cell carcinoma and multiple mieloma: synchronic association with posible immunologic pathogenesis by Cuadra-Urteaga, José Luis, Font Pous, Albert, Pardo-Aranda, Nuria, Rocafiguera, Albert Oriol

Get more information